Crescent Biopharma (NASDAQ:CBIO) Lowered to Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen has downgraded Crescent Biopharma from a "hold" to a "sell" rating, highlighting a shift in analyst sentiment towards the stock.
• Despite the downgrade, other analysts have recently upgraded Crescent Biopharma, with ratings of "strong-buy" from TD Cowen and Lifesci Capital and a target price as high as $28.00.
• The company's latest earnings report showed a significant loss of ($4.93) EPS, missing expectations by over $2, indicating financial struggles.

Crescent Biopharma (NASDAQ:CBIO - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday.

A number of other brokerages also recently commented on CBIO. TD Cowen upgraded shares of Crescent Biopharma to a "strong-buy" rating in a research note on Friday, June 20th. Lifesci Capital raised shares of Crescent Biopharma to a "strong-buy" rating and set a $22.00 price target for the company in a report on Wednesday, June 18th. Stifel Nicolaus initiated coverage on shares of Crescent Biopharma in a research report on Wednesday, June 25th. They set a "buy" rating and a $28.00 target price on the stock. Finally, Wedbush initiated coverage on shares of Crescent Biopharma in a research report on Monday, July 14th. They issued an "outperform" rating and a $27.00 price target on the stock. One analyst has rated the stock with a sell rating, two have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $25.67.

Crescent Biopharma Price Performance

CBIO traded down $0.16 during trading on Friday, reaching $11.84. The company's stock had a trading volume of 130,631 shares, compared to its average volume of 39,199. Crescent Biopharma has a 1 year low of $11.06 and a 1 year high of $63.00. The firm has a market capitalization of $231.47 million, a price-to-earnings ratio of -0.34 and a beta of 1.51.

Crescent Biopharma (NASDAQ:CBIO - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($4.93) EPS for the quarter, missing the consensus estimate of ($2.69) by ($2.24). On average, equities analysts anticipate that Crescent Biopharma will post -0.16 earnings per share for the current fiscal year.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.